Literature DB >> 7680295

Calreticulin synthetic peptide analogues: anti-peptide antibodies in autoimmune rheumatic diseases.

J G Routsias1, A G Tzioufas, M Sakarellos-Daitsiotis, C Sakarellos, H M Moutsopoulos.   

Abstract

Autoantibodies in sera from patients with systemic lupus erythematosus (SLE) and onchocerciasis recognize calreticulin (CaR), a calcium-binding protein, as antigen. In this study we present the immunological properties of two synthetic peptides prepared to correspond to the 1-24 and 7-24 amino acid sequence of CaR. In contrast to information previously reported for the recombinant protein, the CaR-peptide analogues appeared immunoreactive to anti-Ro/SSA autoimmune sera. Human sera from patients with SLE, Sjögren's syndrome (SS), rheumatoid arthritis (RA), as well as mixed connective tissue disease (MCTD), demonstrated a positive autoimmune response (binding of antibodies), to the CaR-peptide analogues. These findings suggest that anti-calreticulin autoantibodies are not restricted to any disease specificity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7680295      PMCID: PMC1554729          DOI: 10.1111/j.1365-2249.1993.tb05921.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  32 in total

Review 1.  Significance of the Ro antigen system.

Authors:  M Reichlin
Journal:  J Clin Immunol       Date:  1986-09       Impact factor: 8.317

2.  Sequence homology of a canine brain calcium-binding protein with calregulin and the human Ro/SS-A antigen.

Authors:  J H Collins; Z J Xi; B H Alderson-Lang; S Treves; P Volpe
Journal:  Biochem Biophys Res Commun       Date:  1989-10-16       Impact factor: 3.575

Review 3.  Autoantibodies in Sjögren's syndrome.

Authors:  J B Harley
Journal:  J Autoimmun       Date:  1989-08       Impact factor: 7.094

4.  Biochemical and immunological heterogeneity of the Ro ribonucleoprotein particles. Analysis with sera specific for the RohY5 particle.

Authors:  G Boire; J Craft
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

5.  Autoimmune response to the Ro/SSA particle is directed to the human antigen.

Authors:  M Reichlin; M Rader; J B Harley
Journal:  Clin Exp Immunol       Date:  1989-06       Impact factor: 4.330

6.  Isolation and characterization of a cDNA clone encoding the 60-kD component of the human SS-A/Ro ribonucleoprotein autoantigen.

Authors:  E Ben-Chetrit; B J Gandy; E M Tan; K F Sullivan
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

7.  Molecular analysis of the 60-kDa human Ro ribonucleoprotein.

Authors:  S L Deutscher; J B Harley; J D Keene
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

Review 8.  Stress proteins, arthritis, and autoimmunity.

Authors:  J B Winfield
Journal:  Arthritis Rheum       Date:  1989-12

9.  Multiple zones in the sequence of calreticulin (CRP55, calregulin, HACBP), a major calcium binding ER/SR protein.

Authors:  M J Smith; G L Koch
Journal:  EMBO J       Date:  1989-12-01       Impact factor: 11.598

10.  A 52-kD protein is a novel component of the SS-A/Ro antigenic particle.

Authors:  E Ben-Chetrit; E K Chan; K F Sullivan; E M Tan
Journal:  J Exp Med       Date:  1988-05-01       Impact factor: 14.307

View more
  9 in total

1.  Fine specificity of autoantibodies to calreticulin: epitope mapping and characterization.

Authors:  P Eggleton; F J Ward; S Johnson; M A Khamashta; G R Hughes; V A Hajela; M Michalak; E F Corbett; N A Staines; K B Reid
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

2.  A novel autoantibody targeting calreticulin is associated with cancer in patients with idiopathic inflammatory myopathies.

Authors:  He Chen; Heng Yang; Qiu-Xiang Cheng; Yong-Peng Ge; Qing-Lin Peng; Ya-Mei Zhang; Gen-Hong Cheng; Guo-Chun Wang; Xin Lu
Journal:  Clin Transl Immunology       Date:  2020-10-15

3.  Calreticulin binds preferentially with B cell linear epitopes of Ro60 kD autoantigen, enhancing recognition by anti-Ro60 kD autoantibodies.

Authors:  E V Staikou; J G Routsias; A A Makri; A Terzoglou; M Sakarellos-Daitsiotis; C Sakarellos; G Panayotou; H M Moutsopoulos; A G Tzioufas
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

4.  Association of calreticulin expression with disease activity and organ damage in systemic lupus erythematosus patients.

Authors:  Yichao Wang; Jiaogui Xie; Zhili Liu; Hongwei Fu; Qianyu Huo; Yajun Gu; Yunde Liu
Journal:  Exp Ther Med       Date:  2017-03-20       Impact factor: 2.447

5.  Epitope mapping with synthetic peptides of 52-kD SSA/Ro protein reveals heterogeneous antibody profiles in human autoimmune sera.

Authors:  V Ricchiuti; J P Briand; O Meyer; D A Isenberg; G Pruijn; S Muller
Journal:  Clin Exp Immunol       Date:  1994-03       Impact factor: 4.330

6.  Epitopes of the Onchocerca volvulus RAL1 antigen, a member of the calreticulin family of proteins, recognized by sera from patients with onchocerciasis.

Authors:  L A Rokeach; P A Zimmerman; T R Unnasch
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

7.  Immunological activity difference between native calreticulin monomers and oligomers.

Authors:  Mi-chun He; Jun Wang; Jian Wu; Fang-yuan Gong; Chao Hong; Yun Xia; Li-juan Zhang; Wan-rong Bao; Xiao-Ming Gao
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

8.  Characterization and use of the ECV304 autoantigenic citrullinome to understand anti-citrullinated protein/peptide autoantibodies in rheumatoid arthritis.

Authors:  Natalia Regine de França; Henri André Ménard; Maximilien Lora; Zhijie Zhou; Joyce Rauch; Carol Hitchon; Luís Eduardo Coelho Andrade; Inés Colmegna
Journal:  Arthritis Res Ther       Date:  2022-01-13       Impact factor: 5.156

9.  Candidate autoantigens identified by mass spectrometry in early rheumatoid arthritis are chaperones and citrullinated glycolytic enzymes.

Authors:  Vincent Goëb; Marlène Thomas-L'Otellier; Romain Daveau; Roland Charlionet; Patrice Fardellone; Xavier Le Loët; François Tron; Danièle Gilbert; Olivier Vittecoq
Journal:  Arthritis Res Ther       Date:  2009-03-10       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.